Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements (2024 and earlier)

Company Profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:42,300,00069,500,00044,300,00078,000,000114,600,00090,100,000
Cash and cash equivalents13,159,00063,458,00016,455,0005,154,00039,196,00045,106,000
Other undisclosed cash, cash equivalents, and short-term investments29,141,0006,042,00027,845,00072,846,00075,404,00044,994,000
Receivables588,000507,000    
Prepaid expense252,000280,000244,000150,000166,000 
Other current assets102,000128,000406,000486,000265,000720,000
Other undisclosed current assets422,000897,000386,000708,000558,000414,000
Total current assets:43,664,00071,312,00045,336,00079,344,000115,589,00091,234,000
Noncurrent Assets
Operating lease, right-of-use asset2,217,0003,190,0001,648,0002,327,000
Property, plant and equipment353,000451,000906,0001,462,0002,180,0002,672,000
Long-term investments and receivables21,877,00034,266,00037,225,000   
Long-term investments21,877,00034,266,00037,225,000   
Other noncurrent assets129,000236,000414,000513,000463,000869,000
Total noncurrent assets:24,576,00038,143,00040,193,0004,302,0002,643,0003,541,000
TOTAL ASSETS:68,240,000109,455,00085,529,00083,646,000118,232,00094,775,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,336,0003,797,0006,069,0004,351,0003,072,0004,633,000
Employee-related liabilities1,846,0002,225,0001,624,000649,000572,000
Accounts payable1,976,0001,565,0003,467,0002,448,0001,998,0003,454,000
Accrued liabilities1,360,000386,000377,000279,000425,000607,000
Debt    878,000  
Deferred rent credit     160,000
Deferred revenue and credits410,000
Other undisclosed current liabilities7,416,0005,895,0006,080,0004,996,0003,795,0003,926,000
Total current liabilities:10,752,0009,692,00012,149,00010,225,0007,027,0008,969,000
Noncurrent Liabilities
Long-term debt and lease obligation:  2,601,0001,232,0002,310,000  
Liabilities, other than long-term debt1,373,000   869,000971,000
Other liabilities     869,000971,000
Operating lease, liability1,373,0002,601,0001,232,0002,310,000
Other undisclosed noncurrent liabilities  (2,601,000)(1,232,000)   
Total noncurrent liabilities:1,373,0002,601,0001,232,0002,310,000869,000971,000
Total liabilities:12,125,00012,293,00013,381,00012,535,0007,896,0009,940,000
Equity
Equity, attributable to parent56,115,00097,162,00072,148,00071,111,000110,336,00084,835,000
Common stock5,0005,0003,0003,0003,0002,000
Additional paid in capital364,361,000361,669,000295,281,000288,224,000280,840,000208,408,000
Accumulated other comprehensive income (loss)(563,000)1,869,0004,00029,000(34,000)(41,000)
Accumulated deficit(307,688,000)(266,381,000)(223,140,000)(217,145,000)(170,473,000)(123,534,000)
Total equity:56,115,00097,162,00072,148,00071,111,000110,336,00084,835,000
TOTAL LIABILITIES AND EQUITY:68,240,000109,455,00085,529,00083,646,000118,232,00094,775,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(32,565,000)(38,630,000)(43,760,000)(48,854,000)(49,222,000)(56,524,000)
Other undisclosed operating income10,005,0004,831,000234,000   
Operating loss:(32,565,000)(38,630,000)(43,760,000)(48,854,000)(49,222,000)(56,524,000)
Nonoperating income
(Investment Income, Nonoperating)
   37,459,000   
Loss from continuing operations before equity method investments, income taxes:(32,565,000)(38,630,000)(6,301,000)(48,854,000)(49,222,000)(56,524,000)
Other undisclosed income (loss) from continuing operations before income taxes(8,742,000)(4,611,000)306,0002,182,0002,283,000861,000
Loss from continuing operations:(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)(55,663,000)
Loss before gain (loss) on sale of properties:(43,241,000)(5,995,000)(46,672,000)(46,939,000)(55,663,000)
Other undisclosed net income      
Net loss:(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)(55,663,000)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, diluted:(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)(55,663,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)(55,663,000)
Comprehensive loss:(41,307,000)(43,241,000)(5,995,000)(46,672,000)(46,939,000)(55,663,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,432,000)1,865,000(25,000)63,0007,000(2,000)
Comprehensive loss, net of tax, attributable to parent:(43,739,000)(41,376,000)(6,020,000)(46,609,000)(46,932,000)(55,665,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: